Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Ventas, Inc.    VTR

Delayed Quote. Delayed  - 09/27 10:03:28 pm
71.96 USD   -1.24%
09/19DJVENTAS : Ernst & Young to Pay $9.3 Million to Settle Charges
09/19 VENTAS : Can Be Used To Generate 12% To 17% Engineered Income
09/14 VENTAS : Announces Pricing of Senior Notes Offering
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 
Latest news on VENTAS, INC.
09/26 VENTAS INC : Other Events (form 8-K)
09/21 VENTAS INC : Other Events, Financial Statements and Exhibits (form 8-K)
09/19DJVENTAS : Ernst & Young to Pay $9.3 Million to Settle Charges
09/19 VENTAS : Can Be Used To Generate 12% To 17% Engineered Income
09/14 VENTAS : Announces Pricing of Senior Notes Offering
09/13 VENTAS, INC. : ex-dividend day
09/08 VENTAS : Wexford Science & Technology to Become an Independent Company
09/01 VENTAS : Completes Acquisition of Wexford’s Life Science and Medical Real ..
08/29 VENTAS : Declares Regular Quarterly Dividend of $0.73 Per Share
07/29 VENTAS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS..
07/29DJVENTAS : Profit Falls Less Than Expected
07/29 VENTAS : reports 2Q results
07/29 VENTAS INC : Results of Operations and Financial Condition, Financial Statements..
07/29 VENTAS : Reports 2016 Second Quarter Results
07/26VENTAS, INC. : half-yearly earnings release
07/11 VENTAS INC : Other Events, Financial Statements and Exhibits (form 8-K)
07/11 VENTAS : Announces Second Quarter 2016 Earnings Release Date and Conference Call
07/07 VENTAS : REIT acquires Wexford assets
07/07 VENTAS : Blackstone sells properties of Baltimore biopark developer for $1.5 bil..
07/06 VENTAS : to acquire South Street Landing investor Wexford for $1.5 billion
07/06 VENTAS : to Acquire Life Science and Medical Real Estate Assets of Wexford for $..
07/06 VENTAS : to Acquire High-Quality Life Science and Medical Real Estate Leased By ..
07/06 BRIEF : Ventas to acquire Wexford's real estate
07/06 VENTAS : Announces Pricing of Common Stock Offering
07/05DJVentas Signs $1.5 Billion Life Sciences-Focused Deal
07/05 VENTAS : Announces Public Offering of 9,000,000 Shares of Common Stock
07/05 VENTAS : to Acquire High-Quality Life Science and Medical Real Estate Leased By ..
07/05DJVENTAS : Signs $1.5 Billion Life Sciences-Focused Deal
06/07 VENTAS INC : Change in Directors or Principal Officers, Financial Statements and..
06/07 VENTAS : Elects Walter C. Rakowich and Roxanne M. Martino to Board of Directors
06/06 VENTAS : to Participate in NAREIT REITWeek 2016 Conference
06/02 VENTAS INC : Other Events, Financial Statements and Exhibits (form 8-K)
06/02 VENTAS : Announces Results of Tender Offer for 1.55% Senior Notes Due 2016
06/02 VENTAS, INC. : ex-dividend day
05/26 VENTAS : Announces Pricing of Senior Notes Offering
05/25 VENTAS INC : Other Events, Financial Statements and Exhibits (form 8-K)
05/25 VENTAS : Commences Tender Offer for 1.55% Senior Notes Due 2016
05/11 VENTAS : Board Appoints James D. Shelton as Presiding Director
04/29 VENTAS : reports 1Q results
04/29 VENTAS INC : Results of Operations and Financial Condition, Financial Statements..
04/29 VENTAS : Reports 2016 First Quarter Results
04/06 VENTAS : Announces First Quarter 2016 Earnings Release Date and Conference Call
04/04 VENTAS : and Kindred In Agreement to Enhance LTAC Portfolio Operated by Kindred
03/10 VENTAS : to Participate in Citi 2016 Global Property CEO Conference
03/03 VENTAS, INC. : ex-dividend day
02/12DJVENTAS' : Profit Rises 15% on Merger Activity
02/12DJVENTAS' : Profit Rises 15% on Merger Activity
02/12 VENTAS : Results of Operations and Financial Condition, Other Events, Financial ..
02/12 VENTAS : reports 4Q results
02/12 VENTAS : Reports 2015 Fourth Quarter and Full Year Results
01/22 VENTAS : Announces Fourth Quarter and Year-End 2015 Earnings Release Date and Co..
01/20 VENTAS : Announces Tax Treatment of 2015 Cash Distributions
01/19 VENTAS : Enables Existing Unitholder Redemptions by Filing of Two Registration S..
01/15 VENTAS : Other Events, Financial Statements and Exhibits (form 8-K)
01/12 VENTAS : CEO to Make Company Presentation at the 34th Annual J.P. Morgan Healthc..
2015 VENTAS, INC. : ex-dividend day
2015 VENTAS : Declares Regular Quarterly Dividend of $0.73 Per Share
2015 Wage pressures coming? U.S. companies start to sound the alarm
2015 VENTAS : to Participate in the NAREIT REITWorld 2015 Conference
2015 VENTAS : Other Events (form 8-K)
2015 VENTAS : to Host Investor Day
2015 VENTAS : Reports 2015 Third Quarter Results
2015DJVENTAS : Misses Third-Quarter Revenue Estimates
2015 VENTAS : reports 3Q results
2015 VENTAS : Reports 2015 Third Quarter Results
2015 VENTAS : Entry into a Material Definitive Agreement, Financial Statements and Ex..
2015 VENTAS : Announces Third Quarter 2015 Earnings Release Date and Conference Call
2015 VENTAS : Change in Directors or Principal Officers (form 8-K)
2015 VENTAS : Promotes Gregory Liebbe to SVP, Chief Accounting Officer and Controller
2015 VENTAS : CEO to Participate in Panel Discussion at BMO Capital Markets North Ame..
2015 VENTAS : Management to Make Company Presentation at Bank of America Merrill Lync..
2015 VENTAS : CEO to Participate in Bank of America Merrill Lynch 2015 Global Real Es..
2015 VENTAS : Chairman and CEO Named One of Healthcare’s 100 Most Influential P..
2015 VENTAS, INC. : ex-dividend day
2015 VENTAS : Names James Mendelson as Lillibridge EVP Asset Management
1  2  3  4  5Next
Advertisement
Financials ($)
Sales 2016 3 371 M
EBIT 2016 791 M
Net income 2016 710 M
Debt 2016 11 111 M
Yield 2016 4,10%
P/E ratio 2016 44,10
P/E ratio 2017 41,60
EV / Sales 2016 10,8x
EV / Sales 2017 10,3x
Capitalization 25 283 M
More Financials
Chart VENTAS, INC.
Duration : Period :
Ventas, Inc. Technical Analysis Chart | VTR | US92276F1003 | 4-Traders
Full-screen chart
Technical analysis trends VENTAS, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 18
Average target price 73,6 $
Spread / Average Target 2,3%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Debra A. Cafaro Chairman & Chief Executive Officer
Robert F. Probst Chief Financial Officer & Executive Vice President
John K. Hart Chief Information Officer & Senior Vice President
Jay M. Gellert Independent Director
James D. Shelton Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
VENTAS, INC.27.52%25 599
WELLTOWER INC11.01%27 488
HCP, INC.1.36%18 516
OMEGA HEALTHCARE INVES..3.66%7 057
HEALTHCARE TRUST OF AM..23.03%4 832
HEALTHCARE REALTY TRUS..21.68%4 084
More Results